Back

Novartis ends Phase 2 ALS trial, exercises $125 million brain-platform option

Verifying
  • Novartis discontinued VHB937’s Phase 2 ALS trial after the drug missed both efficacy endpoints.
  • $125 million is payable to Sironax when the brain-platform transaction closes.
  • Sironax is advancing three Phase 1b/2 programs alongside the platform deal.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Novartis ends Phase 2 ALS trial, exercises $125 million brain-platform option - CoinPost Terminal